Matrixx’s Zicam Sales Up, Ad Spend Burns Profits In Tough Cough/Cold Market
This article was originally published in The Tan Sheet
Executive Summary
First-quarter profits for Matrixx Initiatives were dragged down in part by increased ad spending in the face of a "sharp decline" in sales for the overall cough/cold category, Executive VP and CFO William Hemelt stated in an earnings call April 25
You may also be interested in...
Most OTC Cough Meds Dismissed By Chest Physicians Guidelines
The only effective OTC treatments for acute cough due to the common cold are older antihistamine/ decongestant products such as Wyeth's Dimetapp, according to revised guidelines issued by the American College of Chest Physicians
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement